{
  "meta": {
    "title": "Autacoids_Part_2",
    "url": "https://brainandscalpel.vercel.app/autacoids-part-2-4f1bbd8e.html",
    "scrapedAt": "2025-11-30T11:19:43.308Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1, b-2, c-4, d-3</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1, b-3, c-2, d-4</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">a-2, b-4, c-1, d-3</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1, b-4, c-2, d-3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs with their respective uses.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309405ed74a-6732-40ac-9efd-d76eae9f32e2.jpg\"></span></p>",
      "unique_key": "DT1166642",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166642,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403099b44dd9b-2ee2-413f-a3d3-ea573845dbc7.jpg\">",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">PGI2</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">PGF2&alpha;</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Alpha-1 receptor</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Rho-kinase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old woman is being treated with eye drops for primary open angle glaucoma (POAG). At a follow-up visit, you notice changes in the iris pigmentation as shown below. The prescribed drug most likely acts on which of the following targets?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403093f2ad58f-e710-486b-8624-1d94422afed1.jpg\"></span></p>",
      "unique_key": "DT1166644",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166644,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient is exhibiting <strong>hyperpigmentation of the iris</strong>, which is a <strong>known side effect of prostaglandin analogues</strong>, particularly <strong>latanoprost</strong>, a drug commonly used in <strong>first-line therapy for open-angle glaucoma (OAG)</strong>.</p>\n<ul>\n<li>Latanoprost and similar agents (<strong>bimatoprost, travoprost</strong>) are <strong>PGF2&alpha; analogues</strong>.</li>\n<li>These drugs <strong>increase uveoscleral outflow</strong> of aqueous humor, effectively lowering intraocular pressure.</li>\n<li>They are preferred in OAG due to <strong>once-daily dosing</strong>, <strong>high efficacy</strong>, and <strong>favorable systemic safety profile</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905fcf7de36-6018-4289-8821-2a372bdf03ba.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>PGI2 (Option A): </strong>PGI2 analogues (like epoprostenol) are not used in glaucoma treatment. They are mainly used in <strong>pulmonary arterial hypertension</strong>.</p>\n<p><strong>Alpha-1 (Option C):</strong> Alpha-1 agonists (e.g., phenylephrine) are <strong>mydriatics</strong>, not used for lowering IOP in OAG. However,<strong> alpha-2 agonists</strong> like <strong>brimonidine</strong> <strong>are used in glaucoma</strong>, as they decrease aqueous humor production and increase uveoscleral outflow.</p>\n<p><strong>Rho-kinase (Option D): </strong>While <strong>Rho-kinase inhibitors</strong> (e.g., netarsudil) are newer agents in glaucoma management, they are <strong>not first-line</strong>, and do <strong>not cause iris pigmentation</strong>.</p>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetylcholine</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Arginine</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Isosorbide mononitrate</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitroglycerin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which one of the following is not a nitric oxide (NO) donor, but instead causes NO to be synthesized and released from endogenous precursors, resulting in vasodilation?</span></p>",
      "unique_key": "DT1166649",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166649,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Acetylcholine</strong> is <strong>not a direct nitric oxide donor</strong>. Instead, it promotes <strong>endogenous nitric oxide synthesis</strong>. When acetylcholine binds to <strong>M3 muscarinic receptors</strong> on <strong>vascular endothelial cells</strong>, it activates endothelial nitric oxide synthase (<strong>eNOS</strong>), which converts <strong>L-arginine</strong> into <strong>nitric oxide (NO)</strong>. This NO diffuses into adjacent vascular smooth muscle cells, causing <strong>vasodilation</strong> through activation of <strong>guanylate cyclase</strong> and increased cyclic GMP.</p>\n<p>In contrast, the other given options are either <strong>exogenous NO donors</strong> or precursors:</p>\n<ul>\n<li><strong>Arginine </strong>is the <strong>endogenous substrate</strong> used by <strong>eNOS</strong> to synthesize NO. <strong>(Option B ruled out)</strong></li>\n<li><strong>Isosorbide mononitrate</strong> and <strong>Nitroglycerin</strong> are <strong>organic nitrates</strong>, which act as <strong>NO donors</strong> by releasing nitric oxide directly in the vasculature, thereby bypassing the endothelial synthesis pathway. <strong>(Options C &amp; D ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucuronide-conjugate formation</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Salicylic acid formation</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">N-acetyl-p-benzoquinoneimine formation</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">N-acetylcysteine formation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old woman presents with nausea and vomiting. She has been taking paracetamol (PCM) for knee pain. On examination, she has scleral icterus and tender hepatomegaly. She also appears confused.<br>Her liver function tests show:<br>ALT: 820 U/L <br>AST: 746 U/L<br> ALP: 140 U/L<br>Which of the following is the most likely underlying mechanism of this patient's liver failure?</span></p>",
      "unique_key": "DT1166653",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166653,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>acute liver failure</strong>, characterized by <strong>elevated transaminases (ALT and AST &gt; ALP)</strong>, hepatic encephalopathy (confusion), and signs of hepatocellular injury. Her history of <strong>paracetamol (acetaminophen) use</strong> is highly suggestive of <strong>acetaminophen-induced hepatotoxicity</strong>.</p>\n<p>Acetaminophen is primarily metabolized in the liver via <strong>glucuronidation and sulfation</strong>. However, a small proportion is oxidized by the <strong>cytochrome P450 enzyme CYP2E1</strong>, forming the highly reactive intermediate<strong> N-acetyl-p-benzoquinoneimine (NAPQI)</strong>.</p>\n<ul>\n<li>Under normal conditions, <strong>NAPQI</strong> is detoxified by <strong>glutathione</strong></li>\n<li>In <strong>overdose or chronic high-dose use</strong>, <strong>glutathione stores are depleted</strong>, allowing NAPQI to accumulate.</li>\n<li><strong>NAPQI causes oxidative damage</strong> to hepatocytes, leading to <strong>centrilobular necrosis</strong> and <strong>acute liver failure</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509059a42fb96-6979-415a-a29f-147a26fdad61.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Glucuronide-conjugate formation (Option A): </strong>This is a <strong>normal phase II detoxification pathway</strong> of acetaminophen metabolism. It does <strong>not cause toxicity</strong> and actually helps excrete the drug safely.</p>\n<p><strong>Salicylic acid formation (Option B):</strong>. This is part of <strong>aspirin (salicylate) metabolism</strong>, unrelated to acetaminophen toxicity.</p>\n<p><strong>N-acetylcysteine formation (Option D): N-acetylcysteine (NAC)</strong> is the <strong>antidote</strong> for acetaminophen poisoning. It acts by <strong>restoring glutathione levels</strong> and detoxifying NAPQI. While critical to treatment, it is <strong>not a mechanism of toxicity</strong>.</p>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium with vitamin D</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Omeprazole</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Pyridoxine</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Folic acid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old woman presents with abdominal pain, nausea, and vomiting. She is currently on prednisone and naproxen. On examination, she has a rigid abdomen with rebound tenderness and hypoactive bowel sounds. Labs show a leukocyte count of 13,300/mm3 and an ESR of 70 mm/h. Chest X-ray is taken and is shown below. Treatment with which of the following could have prevented this complication?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030956a783e1-9c78-4cf7-8497-303f0313c8f1.jpg\"></span></p>",
      "unique_key": "DT1166657",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166657,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>perforated peptic ulcer</strong>, evidenced by:</p>\n<ul>\n<li><strong>Pneumoperitoneum</strong> (air under diaphragm on chest X-ray)</li>\n<li><strong>Peritoneal signs</strong> (rigid abdomen, rebound tenderness)</li>\n<li>Use of<strong> NSAIDs (naproxen) and corticosteroids (prednisone),</strong> both of which increase the risk of PUD and its complications\n<ul>\n<li>NSAIDs inhibit COX-1, reducing prostaglandin synthesis and impairing gastric mucosal protection and blood flow. Corticosteroids further impair ulcer healing and, when combined with NSAIDs, significantly increase the risk of complications such as bleeding and perforation.</li>\n<li>Chronic NSAID use increases the risk of PUD approximately fourfold; the addition of corticosteroids amplifies this risk.</li>\n</ul>\n</li>\n</ul>\n<p>Initial management of peptic perforation includes: <strong>NPO</strong>, <strong>IV fluids</strong>, <strong>antibiotics</strong>, and <strong>surgical intervention</strong> (typically laparotomy or laparoscopy)</p>\n<p><strong>Prophylactic treatment with proton pump inhibitors (PPIs)</strong> such as <strong>omeprazole</strong> significantly reduces the risk of NSAID-induced gastric injury and its complications (ulcer, perforation, bleeding). PPIs are <strong>recommended</strong> in all patients on <strong>long-term NSAID or corticosteroid therapy</strong>, especially when taken together.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Calcium with vitamin D (Option A): </strong>While useful for <strong>steroid-induced osteoporosis</strong>, this does <strong>not prevent NSAID- or steroid-induced gastric ulcers or perforation</strong>.</p>\n<p><strong>Pyridoxine (Option C): </strong>Pyridoxine (Vitamin B6) is used to prevent <strong>isoniazid-induced neuropathy</strong>, not GI complications.</p>\n<p><strong>Folic acid (Option D): </strong>Folic acid is used to manage <strong>folate deficiency</strong>, commonly caused by drugs like methotrexate or in pregnancy, not protective against NSAID-induced GI complications.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>H. pylori prophylaxis in PUD:</strong></p>\n<ul>\n<li><strong>Triple regimen</strong> (clarithromycin-sensitive):</li>\n</ul>\n<p><strong>CAMP</strong> - Clarithromycin + (Amoxicillin &lt;&lt; Metronidazole) + PPI - for 2 weeks BD</p>\n<ul>\n<li><strong>Quadruple regimen</strong> (clarithromycin-resistant or failed therapy):</li>\n</ul>\n<p><strong>TOMB</strong> - Tetracycline + Omeprazole + Metronidazole + Bismuth - for 10 days to 6 weeks</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Indomethacin</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Probenecid</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Allopurinol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman presents with a 1-day history of severe pain and swelling of her left great toe. She has had similar episodes sporadically over the past year. Examination shows erythema, warmth, and tenderness of the left first metatarsophalangeal joint. What is the most appropriate next step in treatment?</span></p>",
      "unique_key": "DT1166660",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166660,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>acute monoarthritis</strong> of the <strong>first metatarsophalangeal joint</strong>, a classic presentation of <strong>acute gout</strong>. The sudden onset, joint erythema, warmth, and tenderness suggest <strong>an acute inflammatory response</strong> to <strong>monosodium urate crystal deposition</strong>.</p>\n<ul>\n<li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> are the <strong>first-line therapy</strong> for acute gout flares. <strong>Indomethacin</strong> is a potent NSAID that <strong>reversibly inhibits cyclooxygenase (COX-1 and COX-2)</strong>, blocking prostaglandin synthesis and inflammation.</li>\n<li>NSAIDs are most effective when started early during an acute gout attack. Other first-line treatments include <strong>colchicine</strong> (if started within 36 hours) and <strong>glucocorticoids</strong> (oral or intra-articular), particularly in NSAID-intolerant patients or those with renal contraindications.</li>\n</ul>\n<p>It is important to <strong>avoid initiating urate-lowering therapy (ULT)</strong> like allopurinol or probenecid during an <strong>acute attack</strong>, as these drugs can <strong>exacerbate</strong> or <strong>prolong</strong> the current flare.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option B): </strong>While aspirin is technically an NSAID, <strong>low-dose aspirin </strong>(1-2 g/day) <strong>inhibits uric acid excretion</strong>, thereby <strong>worsening hyperuricemia</strong>. It is contraindicated in acute gout attacks.</p>\n<p><strong>Probenecid (Option C): </strong>Probenecid is a <strong>uricosuric agent</strong> that promotes renal uric acid excretion. It is used in <strong>chronic gout</strong> management but is <strong>not suitable for acute flares</strong>, as it can paradoxically worsen the attack.</p>\n<p><strong>Allopurinol (Option D): </strong>Allopurinol is a <strong>xanthine oxidase inhibitor</strong> used to <strong>prevent gout attacks in chronic hyperuricemia.</strong> However, initiating allopurinol during an acute attack can exacerbate symptoms, and should be deferred until the flare subsides.</p>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Icatibant</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Danazol</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Epsilon aminocaproic acid (EACA)</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Lanadelumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 14-year-old boy is brought in with progressive shortness of breath, difficulty speaking, and diffuse, colicky abdominal pain for the past 3 hours. He had undergone a tooth extraction yesterday. His father has a history of repeated hospitalizations for orofacial swelling. Administration of a drug targeting which of the following is the most appropriate treatment for this patient?</span></p>",
      "unique_key": "DT1166662",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166662,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This clinical presentation is classic for <strong>hereditary angioedema (HAE)</strong>:</p>\n<ul>\n<li>Colicky abdominal pain, dyspnea, orofacial/laryngeal swelling, and a positive family history of similar episodes</li>\n<li>Triggering event: dental procedures are well-known precipitating factors</li>\n<li>HAE is caused by <strong>C1 esterase inhibitor deficiency (Type I) or dysfunction (Type 2)</strong>, leading to uncontrolled activation of kallikrein and <strong>excess bradykinin production</strong>, which increases vascular permeability and results in angioedema.</li>\n</ul>\n<p><strong>Bradykinin is the key mediator</strong> of symptoms in HAE, unlike histamine-mediated angioedema (no urticaria or pruritus).</p>\n<ul>\n<li><strong>Icatibant</strong> is a <strong>bradykinin B2 receptor antagonist</strong>, making it a <strong>first-line treatment for acute HAE attacks</strong>.</li>\n<li>Other first-line options include <strong>C1-INH concentrate</strong> or <strong>kallikrein inhibitors</strong> (e.g., ecallantide).</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030998944d73-2e1e-4bdf-92ff-d62d901acf7e.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Danazol (Option B)</strong> is an <strong>attenuated androgen</strong> that increases hepatic synthesis of C1-INH and is used for <strong>long-term prophylaxis</strong>, not for acute attacks.</p>\n<p><strong>Epsilon aminocaproic acid - EACA (Option C)</strong> is an <strong>antifibrinolytic agent</strong> sometimes used <strong>prophylactically in surgical settings</strong>, but it is <strong>not effective for acute symptom control</strong> in HAE.</p>\n<p><strong>Lanadelumab (Option D) </strong>is a <strong>monoclonal antibody that inhibits plasma kallikrein</strong>, used for <strong>long-term prophylaxis</strong>. It is not a first-line agent for acute episodes.</p>\n<p><strong>Key Takeaway:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509053f83aa18-eeee-4097-9b84-0c2a1d1535d8.png\">",
      "correct_choice_id": 61,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Chlorthalidone</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Lisinopril</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Losartan</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Nifedipine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman presents with facial swelling and difficulty swallowing. She was recently diagnosed with hypertension and started on an antihypertensive drug. Which of the following is the most likely cause of this patient's symptoms?</span></p>",
      "unique_key": "DT1166663",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166663,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient's presentation is characteristic of <strong>ACE inhibitor-induced angioedema</strong>, a known adverse effect of drugs like <strong>lisinopril</strong>.</p>\n<ul>\n<li><strong>Angiotensin-converting enzyme (ACE)</strong> not only converts angiotensin I to angiotensin II but also degrades <strong>bradykinin</strong>.</li>\n<li>ACE inhibitors (like lisinopril) <strong>increase bradykinin levels</strong>, leading to <strong>vasodilation and increased vascular permeability</strong>, which causes <strong>angioedema</strong>, often presenting as <strong>facial swelling</strong>, <strong>tongue swelling</strong>, and <strong>airway compromise</strong>.</li>\n<li>This form of angioedema is <strong>non-allergic</strong> and <strong>not associated with urticaria or pruritus</strong>, distinguishing it from <strong>mast cell-mediated angioedema</strong>.</li>\n<li>Symptoms may occur <strong>shortly after initiation</strong> or <strong>even years after continuous use</strong>.</li>\n<li>It can present with <strong>dysphagia</strong>, <strong>dysphonia</strong>, or even <strong>stridor</strong> in severe cases.</li>\n<li><strong>ARBs</strong> (e.g., <strong>losartan</strong>) do <strong>not affect bradykinin metabolism</strong> and are often used as substitutes when ACE inhibitors cause angioedema.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Chlorthalidone (Option A): </strong>Thiazide diuretics like chlorthalidone are not associated with angioedema. Common side effects include <strong>hypokalemia</strong>, <strong>hyperuricemia</strong>, and <strong>hyperglycemia</strong>.</p>\n<p><strong>Losartan (Option C): </strong>Losartan is an <strong>ARB</strong> and does <strong>not inhibit bradykinin breakdown</strong>. It is generally considered <strong>safe</strong> in patients who have developed ACEI-induced angioedema.</p>\n<p><strong>Nifedipine (Option D):</strong> Nifedipine, a <strong>dihydropyridine calcium channel blocker</strong>, does not affect bradykinin. Side effects include <strong>peripheral edema</strong>, headache, and flushing-not angioedema.</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Withdraw ibuprofen</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ceftriaxone</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Start acyclovir</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Start prednisone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 15-year-old boy presents with headache, nausea, dizziness, fever, conjunctival hyperemia, and blurred vision 30 minutes after taking ibuprofen. He subsequently develops emesis and neck stiffness. Cerebrospinal fluid analysis is normal. What is the next step in management?</span></p>",
      "unique_key": "DT1166667",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166667,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with symptoms suggestive of <strong>meningitis-like syndrome</strong>, but with a <strong>normal CSF analysis</strong> and <strong>rapid onset after ibuprofen intake</strong>, which strongly indicates <strong>Drug-Induced Aseptic Meningitis (DIAM)</strong>.</p>\n<ul>\n<li><strong>DIAM</strong> is a rare, non-infectious inflammatory condition of the meninges associated with various drugs, <strong>especially NSAIDs</strong> like <strong>ibuprofen</strong>, the most commonly implicated agent.</li>\n<li>Clinical features mimic infectious meningitis: <strong>fever, headache, neck stiffness, photophobia, nausea</strong>, and sometimes <strong>altered mental status</strong>.</li>\n<li>The hallmark clue is the <strong>temporal relationship</strong> between drug exposure and onset of symptoms, and <strong>normal or mildly abnormal CSF</strong>.</li>\n</ul>\n<p><strong>Management involves:</strong></p>\n<ul>\n<li><strong>Immediate withdrawal of the offending agent</strong> (in this case, <strong>ibuprofen</strong>), which typically results in <strong>complete resolution</strong> of symptoms within 24-48 hours.</li>\n<li><strong>Antibiotics or antivirals are not indicated</strong> once infectious etiologies are excluded through clinical and laboratory evaluation.</li>\n</ul>\n<p><strong>Potential Causes of Drug-induced Aseptic Meningitis:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309b061fc9e-b02a-4b5e-8939-40515d1081c5.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Start ceftriaxone (Option B): </strong>Ceftriaxone is used for <strong>bacterial meningitis</strong>, which would present with <strong>abnormal CSF</strong> (e.g., high WBCs, elevated protein, low glucose). This patient's CSF is <strong>normal</strong>, and the rapid onset after drug intake further suggests a non-infectious cause.</p>\n<p><strong>Start acyclovir (Option C): </strong>Acyclovir is indicated in <strong>viral (especially HSV) encephalitis</strong>, which typically presents with <strong>altered mental status</strong>, <strong>seizures</strong>, or <strong>temporal lobe findings</strong>, not just meningitic signs. CSF in viral encephalitis usually shows <strong>lymphocytic pleocytosis</strong>, not normal findings.</p>\n<p><strong>Start prednisone (Option D): </strong>Corticosteroids are not the first-line management of DIAM. The condition is <strong>self-limiting</strong> and resolves with <strong>withdrawal of the offending drug</strong>. Steroids may be considered in some autoimmune-mediated aseptic meningitis but not in NSAID-induced DIAM.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Diclofenac</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Nimesulide</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Piroxicam</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Ketorolac</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following NSAIDs undergoes enterohepatic metabolism?</span></p>",
      "unique_key": "DT1166671",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166671,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Piroxicam</strong> is a non-selective NSAID belonging to the oxicam class. One of its unique pharmacokinetic properties is that it undergoes <strong>extensive enterohepatic circulation</strong>, which significantly <strong>prolongs its half-life (~45-50 hours)</strong> and allows for <strong>once-daily dosing</strong>. This also contributes to its <strong>long duration of action</strong>, making it effective in the <strong>management of chronic inflammatory conditions</strong> like osteoarthritis and rheumatoid arthritis.</p>\n<ul>\n<li><strong>Enterohepatic metabolism</strong> refers to the process where a drug is excreted into bile after hepatic metabolism, enters the intestine, and is then <strong>reabsorbed</strong> into systemic circulation, extending the drug's activity.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905f84afadf-442e-40a9-9089-25cd408f1734.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Diclofenac (Option A):</strong> While diclofenac undergoes <strong>hepatic metabolism</strong>, it shows <strong>limited enterohepatic recirculation</strong> and is mostly excreted via urine. Its shorter half-life (~1-2 hours) makes it unsuitable for long-acting effects.</p>\n<p><strong>Nimesulide (Option B):</strong> Nimesulide is metabolized in the liver and excreted mainly in the urine. It does <strong>not exhibit significant enterohepatic circulation</strong>. It is also not recommended for long-term use due to <strong>hepatic toxicity</strong> concerns.</p>\n<p><strong>Ketorolac (Option D):</strong> Ketorolac is a short-acting NSAID, mainly used for <strong>acute pain</strong>, especially post-operative. It undergoes hepatic metabolism and <strong>does not undergo significant enterohepatic recycling</strong>. Its duration of action is short (half-life ~4-6 hours).</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Diclofenac</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Nimesulide</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Piroxicam</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Celecoxib</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old woman presents with pain and swelling in her left knee. She has a history of peptic ulcer disease for which she is taking cimetidine. On examination, there is palpable crepitus and a limited range of motion in the affected joint. X-ray is shown below. Which of the following is the most appropriate pharmacotherapy for this patient's symptoms?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030993b4c046-f5d6-44d7-a7b4-fcccbe837cd2.jpg\"></span></p>",
      "unique_key": "DT1166674",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166674,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with classic features of <strong>knee osteoarthritis (OA)</strong>, both clinically and radiologically:</p>\n<ul>\n<li><strong>Joint space narrowing</strong>, <strong>subchondral sclerosis</strong>, and <strong>osteophyte formation</strong> on X-ray are hallmark features of OA.</li>\n<li>NSAIDs are the mainstay for symptomatic relief in OA. However, the patient's <strong>history of peptic ulcer disease (PUD)</strong> makes <strong>non-selective NSAIDs</strong> risky due to their <strong>COX-1 inhibition</strong>, which impairs gastric mucosal protection.</li>\n</ul>\n<p><strong>Celecoxib</strong> is a <strong>selective COX-2 inhibitor</strong>, offering <strong>anti-inflammatory and analgesic effects</strong> similar to traditional NSAIDs but with <strong>less risk of GI toxicity</strong> since it <strong>spares COX-1</strong>.</p>\n<p>This makes <strong>celecoxib the most appropriate agent</strong> in patients with GI comorbidities like PUD.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509057296fd37-5086-4b31-90d0-db361bcebdad.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Diclofenac (Option A):</strong> A <strong>non-selective NSAID</strong> that inhibits both COX-1 and COX-2. While effective for pain, it carries a <strong>high risk of gastric irritation and ulceration</strong>, which is undesirable in patients with <strong>peptic ulcer disease</strong>.</p>\n<p><strong>Nimesulide (Option B):</strong> Although it has some <strong>COX-2 preference</strong>, it is not a fully selective COX-2 inhibitor. It still poses <strong>GI and hepatic risks</strong>, and is not a safer alternative in a patient with <strong>PUD</strong>.</p>\n<p><strong>Piroxicam (Option C):</strong> A long-acting <strong>non-selective NSAID</strong> associated with <strong>high GI toxicity</strong>, especially in elderly patients and those with a prior history of ulcers. <strong>Not recommended</strong> in this patient population.</p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute pyelonephritis</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephrolithiasis</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Papillary necrosis</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Interstitial nephritis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 36-year-old woman with chronic tension headaches on aspirin presents with several episodes of bilateral flank pain and reddish urine over the past month. Her temperature is 99&deg;F, and blood pressure is 160/90 mm Hg. Physical examination reveals bilateral costovertebral angle tenderness. Laboratory findings show:<br>Hemoglobin: 10.2 g/dL<br>Serum creatinine: 2 mg/dL<br>Urinalysis:<br>1. Protein: +<br>2. RBCs: >12/hpf<br>3. WBCs: 2/hpf<br>Which of the following is the most likely underlying cause of this patient's hematuria?</span></p>",
      "unique_key": "DT1166681",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166681,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient's chronic NSAID use, anemia, renal dysfunction, and painless hematuria with costovertebral angle (CVA) tenderness are characteristic of <strong>renal papillary necrosis,</strong> a hallmark of <strong>analgesic nephropathy.</strong></p>\n<ul>\n<li><strong>Pathophysiology</strong>: NSAIDs like aspirin inhibit cyclooxygenase, <strong>decreasing prostaglandin synthesis. </strong>Prostaglandins normally maintain renal papillary perfusion by<strong> dilating the vasa recta.</strong> The renal papillae are relatively hypovascular and thus prone to ischemic injury, resulting in <strong>necrosis and sloughing</strong> into the collecting system.</li>\n<li><strong>Clinical presentation</strong>: Often includes <strong>flank pain</strong>, <strong>hematuria</strong>, sometimes <strong>sterile pyuria</strong>, and <strong>renal insufficiency</strong>. Sloughed papillae can obstruct the ureters, mimicking renal colic.</li>\n<li>This condition is often <strong>bilateral</strong>, as in this case, and urinalysis typically shows <strong>hematuria</strong>, <strong>mild proteinuria</strong>, and <strong>minimal WBCs</strong>, with or without signs of AKI (elevated creatinine).</li>\n</ul>\n<p><strong>Common causes of renal papillary necrosis include:</strong></p>\n<ul>\n<li>NSAID abuse</li>\n<li>Sickle cell disease or trait</li>\n<li>Diabetes mellitus</li>\n<li>Acute pyelonephritis</li>\n<li>Obstructive uropathy</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acute pyelonephritis (Option A): </strong>Though it may present with <strong>CVA tenderness and hematuria</strong>, it typically causes <strong>fever</strong> and <strong>significant pyuria (WBCs in urine)</strong>. This patient is afebrile with low WBCs in urine, making this less likely.</p>\n<p><strong>Nephrolithiasis (Option B): </strong>Can cause hematuria, but typically causes <strong>colicky, unilateral flank pain</strong>, and may show <strong>microscopic or gross hematuria</strong>. This patient has <strong>bilateral pain</strong> and <strong>NSAID use</strong>, which favors papillary necrosis.</p>\n<p><strong>Interstitial nephritis (Option D): </strong>Though NSAIDs can cause <strong>acute interstitial nephritis</strong>, this is usually associated with <strong>fever</strong>, <strong>rash</strong>, <strong>eosinophilia</strong>, and <strong>pyuria</strong>, especially with <strong>WBC casts</strong> on urinalysis. The <strong>low WBC count</strong> here makes this less likely.</p>\n<p><strong>Key Takeaway:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905f0f6ec6b-9247-4ed9-8189-ae5c965e6d2d.png\">",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Can be combined more safely with an opioid such as codeine</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Does not prolong the bleeding time</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Available in a parenteral formulation that can be injected intramuscularly or intravenously</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Less likely to cause acute renal failure in patients with some preexisting degree of renal impairment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The main advantage of ketorolac over aspirin is that ketorolac:</span></p>",
      "unique_key": "DT1166683",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166683,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Ketorolac</strong> is a potent NSAID with analgesic, anti-inflammatory, and antipyretic properties. It is most widely used for <strong>short-term management </strong>(maximum 5 days) <strong>of moderate to severe pain</strong>, especially in <strong>postoperative settings</strong>, where parenteral administration is preferred.</p>\n<ul>\n<li>Unlike <strong>aspirin</strong>, ketorolac is available in <strong>injectable formulations (both IM and IV)</strong>, making it highly useful for <strong>patients unable to take oral medications</strong> or those requiring <strong>rapid pain relief</strong>.</li>\n<li>This <strong>parenteral availability</strong> is its main advantage over aspirin, which is primarily available in oral and topical forms.</li>\n</ul>\n<p>However, ketorolac <strong>still carries typical NSAID risks</strong>, including:</p>\n<ul>\n<li><strong>Prolonged bleeding time</strong> (due to COX-1 inhibition and reduced thromboxane A2 synthesis). <strong>(Option B ruled out)</strong></li>\n<li><strong>Nephrotoxicity</strong>, especially in patients with <strong>preexisting renal impairment. (Option D ruled out)</strong></li>\n<li>Hence, it should not be used beyond <strong>5 days</strong>, due to increased risk of GI bleeding and nephrotoxicity</li>\n</ul>\n<p>While ketorolac is sometimes used in combination with opioids for additive analgesic effect, it <strong>does not have a superior safety profile in such combinations</strong> compared to aspirin.<strong> (Option A ruled out)</strong></p>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Allopurinol</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Colchicine</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydroxychloroquine</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Probenecid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is most likely to increase serum concentrations of conventional doses of methotrexate, a weak acid that is primarily cleared in the urine?</span></p>",
      "unique_key": "DT1166687",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166687,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Methotrexate is a <strong>weak acid</strong> that undergoes <strong>renal elimination</strong>, largely via <strong>active tubular secretion</strong> in the <strong>proximal tubule</strong>.</p>\n<p><strong>Probenecid</strong>, a uricosuric agent, <strong>inhibits organic anion transporters (OATs)</strong>, especially in the proximal renal tubule, thereby interfering with the <strong>tubular secretion</strong> of weak acids such as <strong>methotrexate</strong> and <strong>penicillin</strong>. By competitively inhibiting this transporter, <strong>probenecid reduces methotrexate clearance</strong>, causing <strong>increased serum concentrations</strong>, and hence may increase the risk of <strong>methotrexate toxicity</strong>.</p>\n<p><strong>Probenecid:</strong></p>\n<ul>\n<li><strong>Mechanism of action:</strong>\n<ul>\n<li>Inhibits <strong>URAT1</strong> transporter in the proximal tubule &rarr; &darr; uric acid reabsorption &rarr; &uarr; uric acid excretion (uricosuric effect)</li>\n<li><strong>Inhibits tubular secretion of weak acids</strong> (e.g., methotrexate, penicillin) &rarr; &uarr; serum concentrations of such drugs</li>\n</ul>\n</li>\n<li><strong>Uses:</strong>\n<ul>\n<li>Treatment of <strong>chronic gout</strong> (not used in acute attacks)</li>\n<li>Historically used to <strong>prolong the action of penicillin</strong> by decreasing its renal clearance</li>\n</ul>\n</li>\n<li><strong>Contraindications:</strong>\n<ul>\n<li><strong>Renal stones (urate nephrolithiasis)</strong></li>\n<li><strong>Renal insufficiency</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Allopurinol (Option A):</strong> Xanthine oxidase inhibitor, used to lower uric acid production. It <strong>does not affect renal tubular secretion of methotrexate</strong>. However, it may increase toxicity of drugs like 6-mercaptopurine.</p>\n<p><strong>Colchicine (Option B): </strong>Used for <strong>acute gout</strong>, acts via inhibition of microtubule polymerization. It <strong>does not interfere with methotrexate excretion</strong>.</p>\n<p><strong>Hydroxychloroquine (Option C): </strong>An antimalarial and immunomodulator used in <strong>SLE and RA</strong>; <strong>no effect on methotrexate excretion</strong>.</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Alcohol abuse</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Gout</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Myocardial infarction</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Peptic ulcer disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following patient characteristics is the most compelling reason for avoiding celecoxib in the treatment of rheumatoid arthritis?</span></p>",
      "unique_key": "DT1166689",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166689,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Celecoxib</strong> is a <strong>COX-2 selective NSAID</strong> that was developed to reduce <strong>gastrointestinal toxicity</strong> compared to non-selective NSAIDs. While it indeed causes fewer GI adverse effects, it is associated with an <strong>increased risk of cardiovascular events</strong>, particularly <strong>arterial thrombotic events</strong> such as myocardial infarction (MI) and stroke.</p>\n<ul>\n<li>COX-2 inhibition leads to reduced prostacyclin (PGI2) production without affecting thromboxane A2 (produced via COX-1), thereby promoting <strong>pro-thrombotic</strong> and <strong>vasoconstrictive</strong> effects.</li>\n<li>Therefore, <strong>a prior history of myocardial infarction is a strong contraindication</strong> to COX-2 inhibitors like celecoxib.</li>\n<li>This cardiovascular risk outweighs its GI protective benefits in such patients.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Alcohol abuse (Option A):</strong> Although alcohol use can increase the risk of hepatotoxicity and GI bleeding with NSAIDs, <strong>celecoxib has less GI toxicity</strong> than non-selective NSAIDs and is not primarily hepatotoxic. Hence, alcohol abuse, while relevant, is <strong>not the most compelling reason</strong> to avoid celecoxib.</p>\n<p><strong>Gout (Option B):</strong> Gout is not a contraindication to celecoxib. In fact, <strong>NSAIDs including selective COX-2 inhibitors</strong> can be used for acute gout attacks, though indomethacin is more commonly used.</p>\n<p><strong>Peptic ulcer disease (Option D):</strong> COX-2 inhibitors like celecoxib are often <strong>preferred</strong> over traditional NSAIDs in patients with <strong>prior PUD</strong> due to their <strong>lower GI risk</strong>, particularly when used with PPIs. However, caution is still warranted in active ulcers.</p>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Allopurinol</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydroxychloroquine</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Probenecid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Over the next 7 months, the patient had two more attacks of acute gout. Her serum uric acid levels were elevated. The decision was made to initiate chronic drug therapy to prevent further attacks. Which of the following drugs can be used to decrease the production of uric acid?</span></p>",
      "unique_key": "DT1166690",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The goal of chronic therapy in gout is to reduce <strong>serum uric acid levels</strong> and prevent further acute attacks.</p>\n<p><strong>Allopurinol</strong> is a <strong>xanthine oxidase inhibitor</strong>, which blocks the conversion of hypoxanthine and xanthine into <strong>uric acid</strong>, thus directly <strong>reducing uric acid production</strong>. It is the drug of choice for <strong>chronic management</strong> in patients with recurrent gout or complications like tophi or uric acid nephropathy.</p>\n<ul>\n<li><strong>Mechanism of Action:</strong> Inhibits <strong>xanthine oxidase</strong> &rarr; &darr; uric acid synthesis</li>\n<li><strong>Key adverse effects:</strong>\n<ul>\n<li><strong>Rash</strong>, including rare but severe <strong>Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)</strong></li>\n<li><strong>Allopurinol Hypersensitivity Syndrome (AHS)</strong>: life-threatening with rash, renal and hepatic dysfunction</li>\n</ul>\n</li>\n<li><strong>Drug interactions:</strong> &uarr; toxicity of <strong>azathioprine</strong> and <strong>6-mercaptopurine</strong> &rarr; dose reduction required</li>\n<li><strong>Allopurinol should never be initiated during an acute gout flare</strong>, as <strong>it may transiently worsen the attack</strong> by altering uric acid levels and triggering further crystal mobilization. Initiation should only occur once the acute episode has fully resolved, and typically with concurrent anti-inflammatory prophylaxis (e.g., colchicine or NSAIDs).</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option B):</strong> <strong>Low-dose aspirin</strong> inhibits renal uric acid excretion, thereby <strong>raising serum uric acid levels</strong>, <strong>contraindicated in gout</strong>.</p>\n<p><strong>Hydroxychloroquine (Option C):</strong> This is an <strong>immunomodulatory drug</strong> used in <strong>rheumatoid arthritis</strong> and <strong>SLE</strong>. It has <strong>no role in uric acid metabolism</strong>.</p>\n<p><strong>Probenecid (Option D):</strong> Probenecid is a <strong>uricosuric agent</strong>, which <strong>increases excretion</strong> of uric acid via renal tubular inhibition of reabsorption. It does <strong>not reduce production</strong>, and is contraindicated in renal dysfunction or uric acid nephrolithiasis.</p>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow suppression and possibly aplastic anemia</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Fever, hepatic dysfunction, and encephalopathy</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperthermia, metabolic acidosis, and coma</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Rapid, fulminant hepatic failure</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-year-old girl presents with symptoms following an aspirin overdose. Which of the following syndromes is this patient most likely to exhibit as a result of this drug overdose?</span></p>",
      "unique_key": "DT1166691",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166691,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Salicylate (aspirin) toxicity</strong> typically presents with a <strong>triad of hyperventilation, metabolic acidosis, and hyperthermia</strong>, especially in <strong>acute overdose in children</strong>.</p>\n<ul>\n<li><strong>Pathophysiology:</strong> Salicylates uncouple oxidative phosphorylation in mitochondria, leading to <strong>increased heat production</strong>, <strong>lactic acidosis</strong>, and <strong>anion gap metabolic acidosis</strong>.</li>\n<li>CNS involvement includes <strong>tinnitus, vertigo</strong>, confusion, and with progression: <strong>seizures, coma</strong>, and potentially death.</li>\n<li>Additional findings may include <strong>tachypnea</strong> (due to direct stimulation of the respiratory center), <strong>dehydration</strong>, <strong>electrolyte disturbances</strong>, and <strong>hypoglycemia</strong>.</li>\n<li>Children are especially vulnerable due to lower detoxification capacity.</li>\n<li>Timely recognition and initiation of treatment with <strong>activated charcoal, correction of acid-base disturbances, </strong>and, if indicated, <strong>hemodialysis</strong> are essential for optimal management.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bone marrow suppression and possibly aplastic anemia (Option A): </strong>This is typically seen with <strong>chloramphenicol toxicity</strong>, not aspirin.</p>\n<p><strong>Fever, hepatic dysfunction, and encephalopathy (Option B): </strong>These findings are more consistent with <strong>Reye's syndrome</strong>, which occurs when aspirin is given to children during or after <strong>viral infections</strong>. However, this is <strong>not the acute overdose presentation</strong> of salicylate toxicity.</p>\n<p><strong>Rapid, fulminant hepatic failure (Option D): </strong>This is characteristic of <strong>acetaminophen (paracetamol) overdose</strong>, which causes centrilobular hepatic necrosis, not salicylate toxicity.</p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclosporine</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Etanercept</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenylbutazone</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfasalazine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a parenterally administered DMARD whose mechanism of anti-inflammatory action is antagonism of tumor necrosis factor?</span></p>",
      "unique_key": "DT1166692",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166692,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Etanercept</strong> is a <strong>biologic DMARD</strong> that exerts its<strong> anti-inflammatory action</strong> <strong>by</strong> <strong>antagonizing TNF-&alpha;</strong>. It is a <strong>fusion protein</strong> composed of the <strong>soluble TNF recepto</strong>r linked to the <strong>Fc portion of IgG1, </strong>which binds circulating TNF-&alpha;, thereby <strong>p</strong>reventing its interaction with cell surface receptors and blocking downstream inflammatory effects.</p>\n<ul>\n<li><strong>Etanercept is administered parenterally (subcutaneously)</strong> and is indicated for:\n<ul>\n<li>Rheumatoid arthritis</li>\n<li>Ankylosing spondylitis</li>\n<li>Psoriatic arthritis</li>\n<li>Plaque psoriasis</li>\n<li>Inflammatory bowel disease (off-label)</li>\n</ul>\n</li>\n<li><strong>It is not a monoclonal antibody (mAb)</strong> like infliximab or adalimumab, but it still inhibits TNF-&alpha; effectively.</li>\n<li><strong>Common adverse effects</strong> include:\n<ul>\n<li>Increased risk of infections, particularly reactivation of latent tuberculosis (hence TB screening is required before initiation)</li>\n<li>Injection site reactions</li>\n<li>Hypersensitivity</li>\n<li>Worsening of heart failure</li>\n</ul>\n</li>\n</ul>\n<p><strong><strong>Explanation of Other Options:</strong></strong></p>\n<p><strong>Cyclosporine (Option A):</strong> It is a <strong>calcineurin inhibitor</strong> that suppresses T-cell activation by blocking IL-2 transcription, not TNF-&alpha; antagonism.</p>\n<p><strong>Phenylbutazone (Option C):</strong> It is a <strong>non-selective NSAID</strong>, now rarely used due to toxicity. It has no disease-modifying or TNF-&alpha; blocking action.</p>\n<p><strong>Sulfasalazine (Option D):</strong> Though used as a <strong>conventional synthetic DMARD</strong>, its mechanism involves suppression of pro-inflammatory cytokines (IL-1, TNF) <strong>indirectly</strong>, not direct TNF antagonism like etanercept.</p>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">High blood pressure</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Rash</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Severe diarrhea</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Sudden gastrointestinal bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Many clinical guidelines recommend treating acute gout with corticosteroids or indomethacin rather than high-dose colchicine because the latter is more likely to cause which of the following adverse effects?</span></p>",
      "unique_key": "DT1166696",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166696,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Colchicine is an anti-inflammatory drug used for both <strong>acute gout flares</strong> and prophylaxis. However, in the <strong>acute setting</strong>, colchicine must be administered in higher doses, which are frequently associated with <strong>dose-limiting gastrointestinal toxicity</strong>.</p>\n<ul>\n<li>The most common adverse effect at therapeutic doses is <strong>severe diarrhea</strong>, often accompanied by nausea, vomiting, and abdominal cramping.</li>\n<li>These side effects occur due to <strong>colchicine's inhibition of microtubule polymerization</strong>, affecting rapidly dividing gastrointestinal epithelial cells.</li>\n<li>Because of this narrow therapeutic index, many guidelines now prefer <strong>NSAIDs (like indomethacin)</strong> or <strong>corticosteroids</strong> for acute gout, especially in older adults or those with renal dysfunction.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>High blood pressure (Option A): </strong>Colchicine is <strong>not associated with hypertension</strong>. This is more commonly a concern with NSAIDs.</p>\n<p><strong>Rash (Option B): </strong>Although <strong>hypersensitivity reactions</strong> can occur, rash is <strong>not a common or dose-limiting side effect</strong> of colchicine.</p>\n<p><strong>Sudden gastrointestinal bleeding (Option D):</strong> GI bleeding is <strong>not typical</strong> of colchicine. It is more likely with <strong>NSAIDs</strong>, particularly in elderly patients or those with peptic ulcer disease.</p>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}